- Neuroelectrics has developed a novel platform to provide personalized therapies for brain disorders using non-invasive brain stimulation
- Neuroelectrics has received approval by the FDA to conduct a clinical trial of brain stimulation therapy at home through telemedicine for patients with Major Depressive Depression (MDD)
- By moving into MDD, Neuroelectrics expands their pipeline and current suite of neurodegenerative products into neuropsychiatry
Cambridge, MA, USA and Barcelona, SP, May 15th: Today Neuroelectrics announced that the FDA has approved the Investigational Device Exemption supplemental protocol study submitted by Neuroelectrics to help patients with Major Depression Disorder (MDD) that cannot access their current non-invasive brain stimulation treatment (rTMS* or ECT**) due to COVID-19 related restrictions.
COVID-19 pandemic has made evident the urgent need for a safe, effective, home-based intervention for patients suffering from a MDD episode. Transcranial direct current stimulation (tDCS) is under investigation on whether it can provide a suitable solution. Neuroelectrics proposed a telehealth study leveraging its unique home-based system enabling supervised, caregiver-delivered tDCS for patients with MDD who cannot access their current treatment due to the pandemic restrictions.
The main purpose of the study is to meet patients’ medical needs providing a home-based tDCS intervention to individuals who are suitable candidates for rTMS or ECT but cannot access these therapies due to the COVID-19 pandemic.
The study will also allow to assess the efficacy, acceptability and treatment compliance of Neuroelectrics’ home-based tDCS system for patients with MDD.
The study Principal Investigator will be Alvaro Pascual-Leone, MD, PhD, Professor of Neurology, Harvard Medical School; Senior Scientist, Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife.
Major depressive disorder (MDD) is highly prevalent and the main cause of global disability worldwide (Kupfer et al., 2012). About 20–40% of patients do not benefit sufficiently from the existing antidepressant interventions, including trials of medication and psychotherapy (Greden, 2001). Pharmacological treatments have limited efficacy, side effects are common (Carvalho et al., 2016), and one-third of patients are medication-resistant failing to achieve remission after using three or more antidepressants (Rush et al., 2006) and experiencing recurrent depressive episodes. (Nemeroff, 2007).
Founded in 2012, Neuroelectrics EEG system (Enobio) received US FDA 510K clearance in May 2017.
Neuroelectrics is currently investigating a novel platform to provide personalized new brain therapies for patients with brain disorders using non-invasive brain stimulation. The unique and proprietary technology monitors the brain’s electrical activity (EEG) and stimulates (tES) brain regions or networks with mild electric currents. The company is moving into a pivotal phase for its Starstim stimulation product for the therapy of treatment-resistant epilepsy.
“We are grateful to the FDA for its fast reaction in COVID times, as a company we are ready to take our platform to patients’ home. Now more than ever telemedicine, brain monitoring and brain stimulation at home is needed, especially for older patients who have even more challenges and restrictions to access clinic or hospital settings”Ana Maiques, Neuroelectrics CEO
Neuroelectrics is developing new personalized brain therapies based on its technology platform: Starstim™. Starstim uses a novel form of non-invasive neuromodulation called transcranial electrical stimulation (tES) to deliver mild electrical currents to the brain. Neuroelectrics’ proprietary Precision-tES™ technology develops a personalized stimulation protocol for each patient, to target the specific areas of the brain based on the treating neurologist diagnosis of the seizure. Starstim-Home™ solution also allows for remote brain monitoring (EEG***).
Neuroelectrics is currently sponsoring an FDA approved clinical trial on medical resistant epilepsy patients (IDE number G160208) at Boston Children’s Hospital (Co-Principal Investigator Alexander Rotenberg, MD, PhD, Associate Professor of Neurology, and Harvard Medical School). Preliminary data presented at American Epilepsy Society Annual Meeting in New Orleans indicated that 75% of patients saw a reduction in seizure frequency of at least 40% from baseline, measured eight weeks after treatment. With this indication Neuroelectrics Starstim aims to become the first FDA approved device for any neurological indication in USA (expected completion of pivotal trial 2021).
For more information please contact Neuroelectrics: email@example.com
*rTMS: repetitive Transcranial Magnetic Stimulation
** ECT: electroconvulsive therapy